Abiragentian acetate liposome composition and preparation method thereof
Through nanoliposome solubilization technology of abiraterone acetate, phospholipids, cholesterol, bile salts and protective agents, the problem of difficulty in dissolution and low bioavailability of abiraterone acetate is solved, and efficient oral absorption and stable preparation are achieved Process reduces cost and equipment dependence.
Patent Information
- Application Number
- CN202411371743.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-22
AI Technical Summary
Abiraterone acetate is difficult to dissolve, complex preparation process, low bioavailability, difficult to guarantee safety and stability, high equipment requirements, high energy consumption and high cost.
Nanoliposome solubilization technology using abiraterone acetate, phospholipids, cholesterol, bile salts and protective agents is used to form flexible liposomes with high deformability and permeability, which improves the water solubility of abiraterone acetate and lipids Biliary salt molecules are embedded in the body membrane to resist the attack of physiological biliary salts of the gastrointestinal tract and promote the absorption of the intestinal mucosa.
It significantly improves the oral bioavailability of abiraterone acetate, simplifies the preparation process, reduces equipment dependence and cost, improves the stability and safety of drugs, and avoids the impact of food and stomach emptying on absorption.
Smart Images

Figure CN118986892A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of new drugs, and in particular to an abiraterone acetate gentian salt liposome composition and a preparation method thereof. Background Art
[0002] Prostate cancer is the most common malignant tumor in the urinary system. Due to its poor prognosis and high malignancy, it has gradually become a major problem that threatens the life and living of elderly men. It is the second most lethal cancer in men after lung cancer and has strong pathological heterogeneity. Metastatic hormone-sensitive prostate cancer is the pre-treatment stage of advanced prostate cancer. Due to the particularity of the hormone-sensitive stage, it is an effective window period for the treatment of advanced prostate cancer. How to extend the hormone-sensitive treatment period is of great significance to prolonging the survival of metastatic prostate cancer in the late stage.
[0003] Abiraterone acetate is a highly selective, irreversible steroidal inhibitor of CYP17 (17α-hydroxylase and C17,20-lyase). It inhibits the synthesis of testosterone in the testicles, adrenal glands and tumors by inhibiting enzyme activity, thereby inhibiting the growth of tumor cells. It is suitable for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received chemotherapy containing docetaxel.
[0004] Abiraterone acetate has high lipophilicity, with a logP of 5.12, and has low permeability on Caco-2 monolayers. It is classified as a BCS IV drug and is soluble in organic solvents but almost insoluble in aqueous media. Its chemical name is: 17-(3-pyridyl)-androstane-5,16-diene-3β-acetate, which is a single enantiomer containing 8 stereochemical elements, and its structure is shown below: .
[0005] The earliest abiraterone-related product to be marketed was abiraterone acetate tablets (trade name: Zytiga) developed by Johnson & Johnson in the United States, with a recommended dose of 1000 mg (4×250 mg) once a day. On April 28, 2011, the FDA approved its combination with prednisone for the treatment of patients with advanced castration-resistant prostate cancer who had a history of docetaxel treatment. In May 2015, the State Food and Drug Administration approved abiraterone acetate for marketing in China. The original research instructions pointed out that food would affect the absorption rate and degree of abiraterone acetate, and it should be taken on an empty stomach at least 1 hour before and at least 2 hours after meals. In addition, abiraterone acetate has extremely poor solubility in the body, and its in vivo bioavailability is about 5%.
[0006] Abiraterone Acetate Tablets (II) (150 mg, 2 tablets / time per day), approved by Hengrui / Chengdu Shengdi Pharmaceutical Co., Ltd. in December 2023, effectively improved the solubility and dissolution rate of the drug by introducing nanocrystal technology and adding the auxiliary material 8-(2-hydroxybenzamido) sodium caprylate absorption promoter, and achieved a breakthrough in oral bioavailability. However, its nanocrystal technology is complex, has high equipment requirements, high energy consumption, and great cost and market limitations.
[0007] Patent CN113616614A discloses an abiraterone acetate soft capsule with an oral bioavailability increased to 12.5 times. Compared with the original drug Zytiga (specification: 250 mg), it does not require a dissolution step in the digestive tract, eliminating the effect of meals. However, in the prescription, caprylic / capric acid mono- and diglycerides account for 60% to 77% of the total mass of the drug contents, Tween 80 accounts for 6% to 15% of the total mass of the drug contents, and Span 80 accounts for 7% to 19% of the total mass of the drug contents. The use of a large amount of oil solvents and surfactants cannot ensure the safety of clinical medication.
[0008] Patent CN110170058B discloses an abiraterone inclusion compound and a preparation method thereof, wherein the solubility of abiraterone acetate is improved by cyclodextrin inclusion, and the molar ratio of abiraterone and 2-hydroxy-β-cyclodextrin in the prescription is (1-2): (1-3). Abiraterone acetate belongs to BCS IV class low solubility-low permeability drugs. The improvement of solubility does not mean the improvement of permeability, and it is difficult to improve bioavailability only by improving solubility. At the same time, cyclodextrin is nephrotoxic, and long-term use is prone to cause accumulation of renal toxicity.
[0009] Therefore, providing an abiraterone acetate preparation with better therapeutic effect has become an urgent problem to be solved in the field. Summary of the invention
[0010] In view of the problems in the prior art that abiraterone acetate is difficult to dissolve, the preparation process is complex, the bioavailability is low, the safety and stability are difficult to ensure, the equipment requirements are high, the energy consumption is large and the cost is high, the present invention provides an abiraterone acetate gentian salt liposome composition and a preparation method thereof, the composition comprises abiraterone acetate, phospholipids, cholesterol, bile salts and protective agents, adopts nanoliposome solubilization, and embeds bile salt molecules in the liposome membrane to form a flexible liposome with high deformability and permeability. The bile salt liposome can resist the attack of physiological bile salts in the gastrointestinal tract while improving the solubility of abiraterone acetate in water, maintain the relative integrity of the liposome membrane, and open the tight connection of gastrointestinal epithelial cells at the same time, promote intestinal mucosal absorption, and double improve oral bioavailability. The obtained abiraterone acetate gentian salt liposome can be used to treat metastatic castration-resistant prostate cancer, and the preparation process is simple, easy to scale up, the freeze-dried powder has high stability, and is convenient for storage and transportation, so it has extremely high industrial application value.
[0011] The abiraterone acetate bile salt liposome composition provided by the present invention comprises abiraterone acetate, phospholipid, cholesterol, bile salt and a protective agent; and the mass ratio of abiraterone acetate:phospholipid:cholesterol:bile salt:protective agent is 1:(8-20):(0.5-5):(0.5-5):(40-150).
[0012] Preferably, the phospholipid is selected from one or more of soybean lecithin, hydrogenated soybean lecithin, and egg yolk lecithin; The bile salt is selected from one or more of sodium deoxycholate, sodium cholate, and sodium glycocholate; The protective agent is selected from one or more of mannitol, glucose and sucrose.
[0013] Furthermore, the liposome composition is a spherical entity, the encapsulation rate of the liposome is greater than 90%, the average particle size is 80 to 140 nm, and the average potential is -20 mV to -40.0 mV.
[0014] The present invention also provides three methods for preparing the abirate gentian salt acetate liposome composition: The first preparation method is the "thin film dispersion method", which includes the following steps: (1) Weighing abiraterone acetate, phospholipids, cholesterol and bile salts, and dissolving them in an organic solvent to obtain a clear and transparent solution, and removing the organic solvent by rotary evaporation to obtain a uniformly dispersed film; (2) Hydrate the film prepared in step (1) with water for injection containing a protective agent; after hydration, extrude the film with a liposome extruder to obtain abiraterone acetate liposome solution; and freeze-dry to obtain abiraterone acetate liposome.
[0015] Preferably, the organic solvent in step (1) is selected from methanol, ethanol or a mixed solvent thereof, and the phospholipid concentration in the solution is 20 to 40 mg / ml; the hydration temperature in step (2) is 0 to 45° C., and the hydration time is 0.5 to 3 h; and the protective agent concentration is 5 to 20 wt %.
[0016] The second method for preparing the abirater gentian salt liposome composition provided by the present invention is the "modified ethanol injection method", also known as the "mixing chamber preparation method", comprising the following steps: (1) Weigh abiraterone acetate, phospholipids, cholesterol and bile salts, and dissolve them in anhydrous ethanol to obtain a clear and transparent solution as the oil phase; (2) Add the protective agent to water for injection, stir and dissolve to form the aqueous phase; (3) The oil phase and the water phase are mixed in a certain proportion, and after injection, the mixture is diluted by half with the water phase of the same concentration in step (2) to allow the oil and water phases to mix fully to obtain liposome colostrum; (4) Ultrafiltration of the liposome colostrum to remove the organic solvent, constant volume to obtain abiraterone acetate liposome solution; and freeze-drying to obtain abiraterone acetate liposome.
[0017] Preferably, the phospholipid concentration in the oil phase in step (1) is 20 to 30 mg / ml, the protective agent concentration in the water phase in step (2) is 5 to 20 wt %, the oil-water mixing volume ratio in step (3) is 1:2 to 1:5, and the ultrafiltration temperature in step (4) is 0 to 45° C.
[0018] The third method for preparing the abirate gentian salt liposome composition provided by the present invention is a "tert-butyl alcohol freeze-drying method", comprising the following steps: (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in tert-butyl alcohol to obtain a clear and transparent solution; freeze-drying to remove the organic solvent to obtain a loose block powder; (2) Hydrate the loose block powder prepared in step (1) with water for injection containing a protective agent. After hydration, extrude the powder with a liposome extruder to obtain abiraterone acetate liposome solution; and freeze-dry to obtain abiraterone acetate liposome.
[0019] Preferably, the phospholipid concentration in the solution in step (1) is 20 to 40 mg / ml, and the protective agent concentration in the aqueous phase in step (2) is 5 to 20 wt%.
[0020] The freeze-drying procedures used in the above three preparation methods are as follows: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40~-45℃ and maintain it for 1.5~3.5h; b. Sublimation drying: evacuate the freeze dryer and maintain a vacuum of 10-20 Pa, raise the temperature of the sample to -20--13°C at 0.5°C / min, and maintain for 10-30 hours; c. Analytical drying: Evacuate the freeze dryer and maintain a vacuum of 1-15 Pa, heat the sample to 20-30 °C at a rate of 0.5 °C / min, and continue drying for 4-8 hours.
[0021] The abirate gentian salt acetate liposome composition provided by the present invention can be used for preparing a drug for treating metastatic castration-resistant prostate cancer.
[0022] In addition, the present invention also provides an oral preparation of abiraterone acetate, which is prepared by the abiraterone acetate gentian salt liposome composition and other excipients commonly used in pharmacy, and the preparation is a tablet (including buccal tablets, orally disintegrating tablets, dispersible tablets, effervescent tablets, ordinary tablets, coated tablets, etc.), granules, oral solution or capsule.
[0023] Compared with the prior art, the beneficial technical effects of the present invention are as follows: (1) The present invention provides an abiraterone acetate liposome, which uses excipients with good physiological compatibility and a simplified formulation design to significantly improve the solubility of abiraterone acetate in water, and has the characteristics of high drug loading, high encapsulation rate, stability and safety.
[0024] (2) The present invention provides an abirate gentian salt liposome, in which bile salt molecules are embedded in the liposome membrane to resist the attack of physiological bile salts in the gastrointestinal tract, maintain the relative integrity of the liposome membrane, prolong the retention time in the intestine, and the liposome is evenly dispersed in the intestine, thereby avoiding the influence of food and gastric emptying on drug absorption; at the same time, the bile salt liposome has a high degree of deformability, can open the tight junctions of gastrointestinal epithelial cells, and promote intestinal mucosal absorption and permeability.
[0025] (3) The abiraterone acetate liposome provided by the present invention is prepared by a thin film dispersion method and can be completed using conventional rotary evaporation equipment. The method is simple and easy to perform, the preparation amount is small, and the cost is saved.
[0026] (4) The present invention provides an innovative pilot-scale scale-up process for abiraterone acetate liposomes, namely the "mixing chamber preparation method", which only requires mixing the oil phase and the water phase at a certain ratio and rate, and then concentrating and removing the organic solvent through an ultrafiltration system to directly obtain a nanoliposome solution with small and uniform particle size. The production process is similar to the preparation process of ordinary water injections and powder injections, with a simple process, low equipment dependence, and easy scale-up.
[0027] (5) Another innovative pilot-scale scale-up process for abiraterone acetate liposomes provided by the present invention is the "tert-butyl alcohol freeze-drying method". The tert-butyl alcohol freeze-drying process replaces the thin film preparation process in the thin film dispersion method, which significantly improves the dispersion uniformity of the drug and excipients and improves the preparation efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The appearance of the lyophilized sample of abiraterone acetate gentian salt liposome prepared by the "thin film dispersion method" in Example 1 is shown in FIG. Figure 2 The appearance of the lyophilized sample of abiraterone acetate gentian salt liposome prepared by the "thin film dispersion method" in Example 1 after reconstitution. Figure 3 This is the particle size distribution diagram of the freeze-dried sample of abiraterone acetate liposome prepared by the "thin film dispersion method" in Example 1 after reconstitution. Figure 4 This is the potential distribution diagram of the lyophilized sample of abiraterone acetate gentian salt liposomes prepared by the "mixing chamber preparation method" in Example 10 after reconstitution. Figure 5 This is a transmission electron micrograph of the lyophilized sample of abiraterone acetate liposome prepared in Example 10 after reconstitution. DETAILED DESCRIPTION
[0029] The beneficial effects of the present invention are further described by the following examples, which are only for illustrative purposes and do not limit the scope of the present invention. At the same time, obvious changes and modifications made by ordinary technicians in the field according to the present invention are also included in the scope of the present invention. In the following examples, unless otherwise specified, percentages are all weight percentages.
[0030] Example 1 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 80mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 50mg Sodium glycocholate 120mg Anhydrous ethanol 15ml Methanol 5ml 10% sucrose aqueous solution 66ml .
[0031] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in a mixed solvent of anhydrous ethanol and methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) is hydrated with a 10% sucrose aqueous solution (20°C to 25°C) for 1 hour; after hydration, the film is extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; and freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome is obtained.
[0032] Figure 1 and Figure 2 The appearance pictures of the abiraterone acetate liposomes obtained in Example 1 and the appearance pictures of the abiraterone acetate liposomes after reconstitution are shown respectively. The liposomes obtained after freeze-drying are in the form of loose blocks, and after reconstitution are in the form of a blue clear liquid; Figure 3 This is the particle size distribution diagram of the abiraterone acetate gentian salt liposome after reconstitution in Example 1, and the average particle size is 108.3 nm.
[0033] Example 2 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 80mg Hydrogenated soybean lecithin (Lipoid S PC-3) 660mg cholesterol 50mg Sodium glycocholate 120mg Anhydrous ethanol 15ml Methanol 5ml 12.5% sucrose aqueous solution 44ml .
[0034] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in a mixed solvent of anhydrous ethanol and methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) was hydrated with a 12.5% sucrose aqueous solution (20°C to 25°C) for 2 hours; after hydration, the film was extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; and freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome was obtained.
[0035] Example 3 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 80mg Soybean lecithin (Lipoid S100) 660mg cholesterol 50mg Sodium glycocholate 120mg Anhydrous ethanol 15ml Methanol 5ml 10% sucrose aqueous solution 55ml .
[0036] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in a mixed solvent of anhydrous ethanol and methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) was hydrated with a 10% sucrose aqueous solution (40°C to 45°C) for 1 hour; after hydration, the film was extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; and freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, and heat the sample at 0.5°C / min to -20 to -13°C and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, and heat the sample at 0.5°C / min to 20 to 30°C and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome was obtained.
[0037] Example 4 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 50mg Sodium deoxycholate 100mg Anhydrous ethanol 15ml Methanol 5ml 10% mannitol aqueous solution 55ml .
[0038] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in a mixed solvent of anhydrous ethanol and methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) is hydrated with a 10% mannitol aqueous solution (0°C to 5°C) for 1 hour; after hydration, the film is extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; and freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, and heat the sample at 0.5°C / min to -20 to -13°C and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, and heat the sample at 0.5°C / min to 20 to 30°C and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome is obtained.
[0039] Example 5 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium Cholate 120mg Anhydrous ethanol 15ml Methanol 5ml 10% glucose in water 55ml .
[0040] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in a mixed solvent of anhydrous ethanol and methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) was hydrated with a 10% glucose aqueous solution (0°C to 5°C) for 1 hour; after hydration, the film was extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; and freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, and heat the sample at 0.5°C / min to -20 to -13°C and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, and heat the sample at 0.5°C / min to 20 to 30°C and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome was obtained.
[0041] Example 6 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium glycocholate 60mg Anhydrous ethanol 20ml 10% sucrose aqueous solution 55ml .
[0042] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in anhydrous ethanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) was hydrated with a 10% sucrose aqueous solution (40°C to 45°C) for 1 hour; after hydration, the film was extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; and freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, and heat the sample at 0.5°C / min to -20 to -13°C and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, and heat the sample at 0.5°C / min to 20 to 30°C and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome was obtained.
[0043] Example 7 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium glycocholate 40mg Methanol 20ml 10% sucrose aqueous solution 55ml .
[0044] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) is hydrated with a 10% sucrose aqueous solution (0°C to 5°C) for 2 hours; after hydration, the film is extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome is obtained.
[0045] Example 8 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 40mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 120mg Sodium glycocholate 60mg Anhydrous ethanol 15ml Methanol 5ml 10% sucrose aqueous solution 55ml .
[0046] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in a mixed solvent of anhydrous ethanol and methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) is hydrated with a 10% sucrose aqueous solution (10°C to 15°C) for 1 hour; after hydration, the film is extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt acetate liposome solution; freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt acetate liposome is obtained.
[0047] Example 9 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium glycocholate 60mg Anhydrous ethanol 15ml Methanol 5ml 10% sucrose aqueous solution 55ml .
[0048] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in a mixed solvent of anhydrous ethanol and methanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) is hydrated with a 10% sucrose aqueous solution (10°C to 15°C) for 1 hour; after hydration, the film is extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt acetate liposome solution; freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt acetate liposome is obtained.
[0049] Example 10 Preparation of Abiraterone Acetate Liposomes Prescription (final prescription of abiraterone acetate liposome solution): Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium glycocholate 60mg 10% sucrose aqueous solution 55ml .
[0050] Preparation process: Mixing cavity preparation method (1) Weigh abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolve them in 22 ml of anhydrous ethanol to obtain a clear and transparent solution as the oil phase; (2) Using 10% sucrose aqueous solution as the aqueous phase; (3) Mix the oil phase and the water phase. The oil phase injection rate is 30 ml / min, the water phase injection rate is 90 ml / min, and the stirring speed is 200 r / min. After the mixing is completed, add 10% sucrose aqueous solution to dilute it by half. The stirring time is 15 minutes to fully mix the oil and water phases to obtain liposome colostrum. (4) The liposome colostrum was concentrated by multiple ultrafiltration with 10% sucrose aqueous solution at 10-15°C until the ethanol concentration was less than 0.001%, and the final volume was adjusted to 55 ml to obtain the abiraterone acetate liposome solution; freeze-dried according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40--45°C and maintain it for 1.5-3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain 10-20 Pa, heat the sample to -20--13°C at 0.5°C / min, and maintain it for 10-30 hours; c. Desorption drying: evacuate the freeze dryer and maintain 1-15 Pa, heat the sample to 20-30°C at 0.5°C / min, and continue drying for 4-8 hours. After freeze-drying, the abiraterone acetate liposome was obtained.
[0051] Figure 4 This is the potential distribution diagram of the abiraterone acetate liposome obtained in Example 10. Its average zeta potential is -33.4 mV, and its physical stability is good. Figure 5 This is a transmission electron microscopy image of Example 10, and the obtained liposomes are spherical.
[0052] Example 11 Preparation of Abiraterone Acetate Liposomes Prescription (final prescription of abiraterone acetate liposome solution): Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium glycocholate 60mg 10% sucrose aqueous solution 55ml .
[0053] Preparation process: Mixing cavity preparation method (1) Weigh abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolve them in 33 ml of anhydrous ethanol to obtain a clear and transparent solution as the oil phase; (2) Using 10% sucrose aqueous solution as the aqueous phase; (3) Mix the oil phase and the water phase. The oil phase injection rate is 30 ml / min, the water phase injection rate is 90 ml / min, and the stirring speed is 200 r / min. After the mixing is completed, add 10% sucrose aqueous solution to dilute it by half. The stirring time is 15 minutes to fully mix the oil and water phases to obtain liposome colostrum. (4) The liposome colostrum was concentrated by multiple ultrafiltration with 10% sucrose aqueous solution at 10-15°C until the ethanol concentration was less than 0.001%, and the final volume was adjusted to 55 ml to obtain the abiraterone acetate liposome solution; freeze-dried according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40--45°C and maintain it for 1.5-3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain 10-20 Pa, heat the sample to -20--13°C at 0.5°C / min, and maintain it for 10-30 hours; c. Desorption drying: evacuate the freeze dryer and maintain 1-15 Pa, heat the sample to 20-30°C at 0.5°C / min, and continue drying for 4-8 hours. After freeze-drying, the abiraterone acetate liposome was obtained.
[0054] Example 12 Preparation of Abiraterone Acetate Liposomes Prescription (final prescription of abiraterone acetate liposome solution): Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium glycocholate 60mg Anhydrous ethanol 22ml 10% sucrose aqueous solution 55ml .
[0055] Preparation process: Mixing cavity preparation method (1) Weigh abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolve them in 22 ml of anhydrous ethanol to obtain a clear and transparent solution as the oil phase; (2) Using 10% sucrose aqueous solution as the aqueous phase; (3) Mix the oil phase and the water phase. The oil phase injection rate is 30 ml / min, the water phase injection rate is 108 ml / min, and the stirring speed is 200 r / min. After the mixing is completed, add 10% sucrose aqueous solution to dilute it by half. The stirring time is 15 minutes to fully mix the oil and water phases to obtain liposome colostrum. (4) The liposome colostrum was concentrated by multiple ultrafiltration with 10% sucrose aqueous solution at 10-15°C until the ethanol concentration was less than 0.001%, and the final volume was adjusted to 55 ml to obtain the abiraterone acetate liposome solution; freeze-dried according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40--45°C and maintain it for 1.5-3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain 10-20 Pa, heat the sample to -20--13°C at 0.5°C / min, and maintain it for 10-30 hours; c. Desorption drying: evacuate the freeze dryer and maintain 1-15 Pa, heat the sample to 20-30°C at 0.5°C / min, and continue drying for 4-8 hours. After freeze-drying, the abiraterone acetate liposome was obtained.
[0056] Example 13 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Sodium glycocholate 60mg Tert-Butanol 20ml 10% sucrose aqueous solution 66ml .
[0057] Preparation process: tert-butyl alcohol freeze-drying method (1) Weigh abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolve them in tert-butanol to obtain a clear and transparent solution; freeze-dry according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample to -20 to -13°C at 0.5°C / min, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample to 20 to 30°C at 0.5°C / min, and continue drying for 4 to 8 hours. After freeze-drying, a loose block powder is obtained; (2) Hydrate the loose block powder prepared in step (1) with a 10% sucrose aqueous solution (20°C to 25°C) for 1 hour; after hydration, extrude the powder through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; freeze-dry according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome is obtained.
[0058] Example 14 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 80mg Hydrogenated soybean lecithin (Lipoid S PC-3) 660mg cholesterol 50mg Sodium glycocholate 120mg Tert-Butanol 20ml 12.5% sucrose aqueous solution 44ml .
[0059] Preparation process: tert-butyl alcohol freeze-drying method (1) Weigh abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolve them in tert-butanol to obtain a clear and transparent solution; freeze-dry according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample to -20 to -13°C at 0.5°C / min, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample to 20 to 30°C at 0.5°C / min, and continue drying for 4 to 8 hours. After freeze-drying, a loose block powder is obtained; (2) Hydrate the loose block powder prepared in step (1) with a 12.5% sucrose aqueous solution (20°C to 25°C) for 1 hour; after hydration, extrude the powder through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; freeze-dry according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome is obtained.
[0060] Example 15 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 80mg Soybean lecithin (Lipoid S100) 660mg cholesterol 50mg Sodium glycocholate 120mg Tert-Butanol 20ml 10% sucrose aqueous solution 55ml .
[0061] Preparation process: tert-butyl alcohol freeze-drying method (1) Weigh abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolve them in tert-butanol to obtain a clear and transparent solution; freeze-dry according to the procedure: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 2.5 to 3 hours; b. Sublimation drying: evacuate the freeze dryer and maintain 10 to 20 Pa, heat the sample to -20 to -13°C at 0.5°C / min, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain 1 to 15 Pa, heat the sample to 20 to 30°C at 0.5°C / min, and continue drying for 4 to 8 hours. After freeze-drying, a loose block powder is obtained; (2) Hydrate the loose block powder prepared in step (1) with a 10% sucrose aqueous solution (40°C to 45°C) for 1 hour; after hydration, extrude the powder through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abirater gentian salt liposome solution; freeze-dry according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, the abirater gentian salt liposome is obtained.
[0062] Comparative Example 1 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 55mg Egg yolk lecithin (Lipoid E80) 660mg cholesterol 100mg Anhydrous ethanol 20ml 10% sucrose aqueous solution 55ml .
[0063] Preparation process: thin film dispersion method (1) Weighing abiraterone acetate, phospholipids, and cholesterol and dissolving them in anhydrous ethanol to obtain a clear and transparent solution; then performing rotary evaporation to remove the organic solvent to obtain a uniformly dispersed film; (2) The film prepared in step (1) was hydrated with a 10% sucrose aqueous solution (10°C to 15°C) for 1 hour; after hydration, the film was extruded through filter membranes with pore sizes of 800 nm, 400 nm, 200 nm, and 100 nm in sequence using a liposome extruder to obtain an abiraterone acetate liposome solution; freeze-dried according to the following procedures: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40 to -45°C and maintain it for 1.5 to 3.5 hours; b. Sublimation drying: evacuate the freeze dryer and maintain it at 10 to 20 Pa, heat the sample at 0.5°C / min to -20 to -13°C, and maintain it for 10 to 30 hours; c. Desorption drying: evacuate the freeze dryer and maintain it at 1 to 15 Pa, heat the sample at 0.5°C / min to 20 to 30°C, and continue drying for 4 to 8 hours. After freeze-drying, abiraterone acetate liposomes were obtained.
[0064] Comparative Example 2 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 100mg Soy lecithin 600mg cholesterol 100mg Chloroform 5ml pH 6.8 phosphate buffer 10ml .
[0065] Preparation process: Soy lecithin, abiraterone acetate and cholesterol were mixed according to the prescribed amount, ultrasonically dissolved in chloroform, and rotary evaporated in a 40°C water bath for about 40 minutes to remove the organic solvent. After drying, pH 6.8 phosphate buffer was added and shaken vigorously until a milky white suspension was formed. It was ultrasonically treated for 1 hour, cooled at room temperature, and allowed to stand overnight. The next day, it was centrifuged at 3500 rpm for 60 minutes, and the precipitate was dried in a rotary vacuum dryer.
[0066] Comparative Example 3 Preparation of Abiraterone Acetate Liposomes prescription: Abiraterone acetate 100mg Soy lecithin 600mg cholesterol 100mg Sodium glycocholate 150mg Chloroform 5ml pH 6.8 phosphate buffer 10ml .
[0067] Preparation process: Soy lecithin, abiraterone acetate, sodium glycocholate and cholesterol were mixed according to the prescribed amount, ultrasonically dissolved in chloroform, and evaporated in a 40°C water bath for about 40 minutes to remove the organic solvent. After drying, pH 6.8 phosphate buffer was added and shaken vigorously until a milky white suspension was formed. It was ultrasonically treated for 1 hour, cooled at room temperature, and allowed to stand overnight. The next day, it was centrifuged at 3500 rpm for 60 minutes, and the precipitate was dried in a rotary vacuum dryer.
[0068] Experimental Example 1 Sample Encapsulation Efficiency Determination Method Take 1 ml of liposome solution in a 0.22um microporous membrane centrifuge tube and centrifuge at 3000r / min for 10min; accurately measure 0.5 ml of filtrate to a 10ml volumetric flask with methanol to break the emulsion, make up to volume, and shake well; measure the content by HPLC, and calculate the encapsulation efficiency (EE) according to the following formula. The results are shown in Table 1. .
[0069] Experimental Example 2 Sample content determination method Reference solution: Accurately weigh 10 mg of abiraterone acetate API into a 100 ml volumetric flask, add methanol to dissolve and make up to volume to prepare a 100 ug / ml solution as the reference solution.
[0070] Test solution: Accurately measure 2 ml of abiraterone acetate liposome solution, place it in a 10 ml volumetric flask, add methanol to ultrasonically break the emulsion and make up to volume, shake well, and use it as the test solution.
[0071] Liquid phase conditions: octadecylsilane bonded silica gel column (4.6 mm × 250 mm, 5 μm); mobile phase: acetonitrile-methanol (20:80); detection wavelength 220 nm; flow rate 1.0 ml / min; injection volume 10 ul; column temperature 40 ° C. The experimental results are shown in Table 1.
[0072] Table 1 Test results of properties of abiraterone acetate liposomes in examples and comparative examples .
[0073] The results show that the abiraterone acetate liposomes prepared in Examples 1 to 15 of the present invention and Comparative Example 1 have high encapsulation efficiency, nanometer-level particle size, and good stability. The abiraterone acetate liposomes prepared in Comparative Examples 2 and 3 are difficult to achieve effective drug encapsulation, have micrometer-level particle size, and poor stability.
[0074] Experimental Example 3 Pharmacokinetic Test Test samples: Examples 1 to 15 and Comparative Example 1. Reference preparation: Abiraterone acetate tablets (Zeko, 250 mg / tablet). Twelve healthy Beagle dogs, weighing 9 to 15 kg, were divided into two groups and were allowed to drink water freely during the test. The fasting group fasted for more than 12 hours before administration, and was given 10 ml of warm water at the same time as administration, and fed 6 hours after administration; the postprandial group was fed quantitatively by gastric tube 30 minutes before administration. Administer 250 mg of abiraterone acetate orally, and 1.0 ml of blood was collected from the forelimb or hindlimb vein at 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, and 24 hours after administration. The blood collection points must be rotated at the venous blood collection sites of the four limbs, and do not repeat the same site. The plasma was collected by heparin sodium anticoagulation and centrifugation, and its blood drug concentration was determined to calculate the fasting group C max , AUC, and compared with the reference preparation and the postprandial group. The results are shown in Table 2; AUC is the integral area of the curve with blood drug concentration as the ordinate and time as the abscissa; C max It is the maximum blood drug concentration on the curve after administration.
[0075] Table 2 Comparison of pharmacokinetic parameters of Examples 1 to 15 and Comparative Example 1 and Zeke@ .
[0076] It can be seen from Table 2 that the abiraterone acetate liposomes provided by the present invention are compared with the abiraterone acetate tablets provided by Zeke@ abiraterone acetate tablets. max The results showed that the bioavailability of abiraterone liposomes was excellent in vivo after administration, and the AUC and C max In contrast, the absorption effect of the abiraterone liposomes of the present invention is less affected by eating. However, the liposomes of Comparative Example 1 without adding bile salts have no significant difference from the original research, but the difference is large before and after meals.
[0077] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any equivalent substitutions, modifications, etc. made by technicians in this field without any creative work within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A liposome composition of abiraterone acetate, characterized in that: It contains abiraterone acetate, phospholipids, cholesterol, bile salts and protective agents, and the mass ratio of abiraterone acetate: phospholipids: cholesterol: bile salts: protective agents is 1: (8-20): (0.5-5): (0.5-5): (40-150).
2. The abiraterone acetate liposome composition according to claim 1, characterized in that: The phospholipids are one or more of soybean lecithin, hydrogenated soybean lecithin, and egg yolk lecithin; The bile salt is one or more of sodium deoxycholate, sodium cholate, and sodium glycocholate; The protective agent is one or more of mannitol, glucose and sucrose.
3. The abiraterone acetate liposome composition according to claim 1, characterized in that: The liposome is a spherical entity; the encapsulation rate of the liposome is greater than 90%; the average particle size of the liposome is 80nm to 140nm; and the average potential of the liposome is -20.0mV to -40.0mV.
4. The method for preparing the abiraterone acetate liposome composition according to claim 1, characterized in that: The thin film dispersion method is used for preparation, which includes the following steps: (1) Weighing abiraterone acetate, phospholipids, cholesterol and bile salts, and dissolving them in an organic solvent to obtain a clear and transparent solution, and removing the organic solvent by rotary evaporation to obtain a uniformly dispersed film; (2) Hydrate the film prepared in step (1) with water for injection containing a protective agent; after hydration, extrude the film with a liposome extruder to obtain abiraterone acetate liposome solution, and freeze-dry to obtain abiraterone acetate liposome.
5. The method for preparing the abirate gentian acetate liposome composition according to claim 4, characterized in that: The organic solvent in step (1) is selected from methanol, ethanol or a mixed solvent thereof, and the phospholipid concentration in the solution is 20 to 40 mg / ml; the hydration temperature in step (2) is 0°C to 45°C, and the hydration time is 0.5 to 3 hours; and the protective agent concentration is 5 to 20 wt%.
6. The method for preparing the abirate gentian acetate liposome composition according to claim 1, characterized in that: The modified ethanol injection method includes the following steps: (1) Weighing abiraterone acetate, phospholipids, cholesterol and bile salts, and dissolving them in anhydrous ethanol to obtain a clear and transparent solution as the oil phase, wherein the phospholipid concentration in the oil phase in step (1) is 20 to 30 mg / ml; (2) adding the protective agent to water for injection, stirring and dissolving, and using the aqueous phase as the protective agent concentration in the aqueous phase of step (2) is 5 to 20 wt %; (3) The oil phase and the water phase are mixed in a certain volume ratio, and after injection, the mixture is diluted by half with the water phase of the same concentration in step (2) to allow the oil and water phases to mix fully to obtain liposome colostrum; the volume ratio of the oil and water phases in step (3) is 1:2 to 1:5; (4) Ultrafiltration of the liposome colostrum to remove the organic solvent, constant volume, to obtain abirater gentian salt acetate liposome solution; freeze drying to obtain abirater gentian salt acetate liposome; the ultrafiltration temperature in step (4) is 0°C to 45°C.
7. The method for preparing the abiraterone acetate liposome composition according to claim 1, characterized in that: The preparation method is prepared by tert-butyl alcohol freeze-drying method, comprising the following steps: (1) Weighing abiraterone acetate, phospholipids, cholesterol, and bile salts and dissolving them in tert-butyl alcohol to obtain a clear and transparent solution; freeze-drying to remove the organic solvent to obtain a loose block powder, wherein the phospholipid concentration in the solution in step (1) is 20 to 40 mg / ml; (2) Hydrate the loose block powder prepared in step (1) with water for injection containing a protective agent, extrude the powder with a liposome extruder after hydration to obtain abirate gentian salt liposome solution; and freeze-dry to obtain abirate gentian salt liposome. The concentration of the protective agent in the aqueous phase of step (2) is 5 to 20 wt%.
8. The method for preparing the abiraterone acetate liposome composition according to any one of claims 4, 6 or 7, characterized in that: The freeze-drying procedure is as follows: a. Pre-freezing: first cool the sample solution to be freeze-dried to -40~-45℃ and maintain it for 1.5~3.5h; b. Sublimation drying: evacuate the freeze dryer and maintain a vacuum of 10-20 Pa, raise the temperature of the sample to -20--13°C at 0.5°C / min, and maintain for 10-30 hours; c. Analytical drying: Evacuate the freeze dryer and maintain a vacuum of 1-15 Pa, heat the sample to 20-30 °C at a rate of 0.5 °C / min, and continue drying for 4-8 hours.
9. Use of the abirate gentian acetate liposome composition according to claim 1 in the preparation of a medicament for treating metastatic castration-resistant prostate cancer.
10. Use of the abiraterone acetate liposome composition according to claim 9 in the preparation of a medicament for treating metastatic castration-resistant prostate cancer, characterized in that: It also includes an oral preparation of the abirate gentian salt acetate liposome composition, which is made of the abirate gentian salt acetate liposome and other pharmaceutical excipients, and the preparation is in the form of tablets, granules, oral solutions or capsules.
Citation Information
Patent Citations
Deoxidated podophyllotoxin long-circulating liposome freeze-drying preparation
CN104382856A
Polysaccharide and bile salt lipidosome for oral administration and preparation method of lipidosome
CN107007553A
Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
CN112654348A
Butylphthalide nano-liposome freeze-dried powder injection and preparation method thereof
CN116459224A
